GENNIEFY
Market News
Latest financial news and analysis from global markets
INTC
Iren vs. Nebius: Which Neocloud Provider Is the Better AI Stock?
Both neocloud leaders stand to benefit from rising demand for AI computing power.
NVDA
Iren vs. Nebius: Which Neocloud Provider Is the Better AI Stock?
Both neocloud leaders stand to benefit from rising demand for AI computing power.
GS
Best CD rates today, Saturday, May 2, 2026 (best account provides 4.05% APY)
If you're searching for today's best CD rates, Saturday, May 2, 2026, we've narrowed down some of the top offers. Learn more about the best CD rates today.
INTC
The Warren Buffett Approved ETF Every Long-Term Investor Should Own
The Oracle of Omaha understands that most people just don't have the time, experience, or insight that he has when it comes to managing a market-beating portfolio.
NVDA
The Warren Buffett Approved ETF Every Long-Term Investor Should Own
The Oracle of Omaha understands that most people just don't have the time, experience, or insight that he has when it comes to managing a market-beating portfolio.
NVDA
UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog
The Procure Space ETF (NYSEARCA:UFO) was built to give investors a single ticket to a fragmented industry: rocket builders, satellite operators, ground-segment vendors, and direct-to-device communications upstarts that rarely fit cleanly into a sector ETF. The prospectus is direct about the design, requiring at least 80% of index weight in companies that derive a majority ... UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog
NVDA
Can Europe Compete With SpaceX Launch Price? Only If Elon Musk Says "Yes."
Don't believe everything you read. ArianeGroup still cannot compete with SpaceX on price.
INTC
Can Europe Compete With SpaceX Launch Price? Only If Elon Musk Says "Yes."
Don't believe everything you read. ArianeGroup still cannot compete with SpaceX on price.
AMZN
Amazon Opens Audible Story House As Shares Trade Below Targets
Amazon.com (NasdaqGS:AMZN) plans to open Audible Story House, a bookless bookstore and audio listening lounge, in New York City. The new space will serve as Audible's first dedicated physical retail location, focused on listening stations, live events, and community gatherings. The move represents a fresh push into bricks and mortar for Amazon's audio brand following prior pullbacks in physical bookstores. For readers watching NasdaqGS:AMZN, the Audible Story House concept arrives as...
COST
Will Costco’s Membership Resilience and Value Strategy Shift Costco Wholesale's (COST) Investment Narrative?
In recent months, Costco Wholesale has reported resilient performance powered by high membership renewal rates, rising executive memberships, new prepared-meal offerings, and value-focused pricing such as holding its iconic US$1.50 hot dog combo steady while adding a bottled water option. At the same time, developments like Vanguard’s large passive stake and lawsuits over potential tariff refunds highlight how Costco’s member-first model and pricing choices are drawing attention from both...
MRNA
A Look At Moderna (MRNA) Valuation After Q1 2026 Earnings And New Vaccine Approvals
Moderna (MRNA) is back in focus after its Q1 2026 earnings, reporting revenue of US$389 million compared with US$108 million a year earlier and a wider net loss of US$1.343 billion driven by litigation costs. See our latest analysis for Moderna. That backdrop of Q1 approvals, pipeline progress and a large litigation charge has come alongside a 1 day share price return of 1.24% decline, a 7 day share price return of 10.57% decline and a year to date share price return of 47.02%. Meanwhile, the...
GILD
Assessing Gilead Sciences (GILD) Valuation As Long Term Returns Contrast With Recent Share Performance
What recent performance suggests about Gilead Sciences (GILD) With no single headline event in focus, attention on Gilead Sciences (GILD) has centered on its recent share performance and business profile, prompting investors to reassess how the biopharma stock fits into their portfolios. See our latest analysis for Gilead Sciences. Gilead Sciences’ share price has eased in recent months, with a 30 day share price return of 6.17% and a 90 day share price return of 7.26%. However, the 1 year...